Abstract
In real-world settings, many patients experience single or multiple recurrences of non-cardiogenic cerebral infarction, which is mainly caused by arteriosclerosis. These patients are treated according to set guidelines. While antiplatelet therapy is the standard treatment for preventing recurrence, this therapy alone is insufficient for full prevention of recurrence. Combining the administration of antiplatelet agents with the management of risk factors for recurrent cerebral infarction can maximize the preventive effects of these drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
